Your browser is no longer supported. Please, upgrade your browser.
Settings
EDSA Edesa Biotech, Inc. daily Stock Chart
EDSA [NASD]
Edesa Biotech, Inc.
Index- P/E- EPS (ttm)-0.72 Insider Own6.10% Shs Outstand8.74M Perf Week34.41%
Market Cap86.40M Forward P/E- EPS next Y-1.16 Insider Trans1.43% Shs Float4.71M Perf Month45.77%
Income-4.80M PEG- EPS next Q-0.21 Inst Own24.50% Short Float1.10% Perf Quarter178.31%
Sales0.60M P/S143.99 EPS this Y94.80% Inst Trans- Short Ratio0.03 Perf Half Y119.57%
Book/sh0.79 P/B8.95 EPS next Y-70.60% ROA-75.30% Target Price- Perf Year54.70%
Cash/sh- P/C- EPS next 5Y- ROE-85.40% 52W Range1.58 - 19.10 Perf YTD72.44%
Dividend- P/FCF- EPS past 5Y58.90% ROI- 52W High-58.77% Beta0.57
Dividend %- Quick Ratio- Sales past 5Y2.00% Gross Margin81.70% 52W Low398.42% ATR1.38
Employees10 Current Ratio12.80 Sales Q/Q0.00% Oper. Margin- RSI (14)64.36 Volatility33.82% 15.02%
OptionableNo Debt/Eq0.00 EPS Q/Q45.20% Profit Margin- Rel Volume0.30 Prev Close7.07
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.79M Price7.88
Recom- SMA2039.52% SMA5061.55% SMA200105.93% Volume509,537 Change11.39%
Jul-30-20 07:45AM  
Jun-15-20 08:15AM  
May-27-20 07:20AM  
May-19-20 06:47AM  
May-15-20 08:00AM  
Apr-24-20 08:35AM  
Apr-20-20 09:00AM  
Apr-02-20 10:33AM  
Mar-12-20 07:30AM  
Feb-13-20 04:10PM  
Jan-06-20 09:21AM  
Dec-12-19 04:30PM  
Dec-03-19 07:30AM  
Nov-05-19 07:30AM  
Oct-21-19 07:30AM  
Aug-29-19 08:30AM  
Aug-14-19 04:05PM  
Jul-25-19 07:30AM  
Jun-20-19 12:12PM  
08:26AM  
07:30AM  
07:30AM  
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the development and advancement of treatments for dermatological and gastrointestinal indications. Its lead product candidate is EB01, a non-steroidal anti-inflammatory molecule to treat chronic allergic contact dermatitis. Edesa Biotech, Inc. has a collaborative research project with the National Research Council of Canada to develop novel immunotherapies for vitiligo, as well as other indications; and Light Chain Bioscience for the development and commercialization of two Phase 2-ready biologic drug candidates for various therapeutic, prophylactic, and diagnostic applications. The company was founded in 2015 and is headquartered in Markham, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Brooks Michael JPresidentMay 27Buy3.002,5007,4994,327May 29 09:20 AM
Nijhawan PardeepChief Executive OfficerMay 26Buy2.983,0008,9392,124,024May 28 12:19 PM
Nijhawan PardeepChief Executive OfficerMar 17Buy1.875,0009,3732,121,024Mar 19 10:34 AM
Sistilli CarloDirectorJan 08Buy4.112,43610,0122,436Jan 10 02:13 PM
van der Velden PeterDirectorJan 08Buy3.20140,625450,0001,833,066Jan 10 02:13 PM
JOHNSON LORIN KDirectorJan 08Buy4.118,52435,0348,524Jan 10 02:11 PM
Brooks Michael JPresidentJan 08Buy4.111,8277,5091,827Jan 10 02:09 PM